MKI67 and neoplasm: Preoperative assessment of the Ki‐67 index by EUS–FNA may help to identify patients with marginally resectable tumours based on clinical criteria, who may benefit more from neoadjuvant chemotherapy than upfront surgery, given the high risk of early postoperative recurrence (those with a Ki‐67 index above 50 per cent), although the feasibility of this should be investigated further.